Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 study.
Haranaka M, Momose A, Nakayama Y, Saito Y, Spiessens B, Davies TA, Dobbelsteen GVD, Poolman J, Sarnecki M. Haranaka M, et al. Among authors: sarnecki m. J Infect Chemother. 2025 Jan;31(1):102514. doi: 10.1016/j.jiac.2024.09.003. Epub 2024 Sep 5. J Infect Chemother. 2025. PMID: 39243886 Free article. Clinical Trial.
Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive Escherichia Coli Disease in Patients Admitted in Tertiary Care Hospitals.
Doua J, Geurtsen J, Rodriguez-Baño J, Cornely OA, Go O, Gomila-Grange A, Kirby A, Hermans P, Gori A, Zuccaro V, Gravenstein S, Bonten M, Poolman J, Sarnecki M. Doua J, et al. Among authors: sarnecki m. Open Forum Infect Dis. 2023 Jan 27;10(2):ofad026. doi: 10.1093/ofid/ofad026. eCollection 2023 Feb. Open Forum Infect Dis. 2023. PMID: 36817744 Free PMC article.
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Fierro CA, Sarnecki M, Doua J, Spiessens B, Go O, Davies TA, van den Dobbelsteen G, Poolman J, Abbanat D, Haazen W. Fierro CA, et al. Among authors: sarnecki m. Open Forum Infect Dis. 2023 Aug 11;10(8):ofad417. doi: 10.1093/ofid/ofad417. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37608916 Free PMC article.
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study.
Doua J, Ekkelenkamp M, Verheij T, Go O, Ruhmel S, Leathers K, Spiessens B, van Rooij S, Fowler VG Jr, Geurtsen J, Dolor R, Sarnecki M, Chatterjee R, Poolman J, Bonten M; on behalf COMBACTE-NET consortium/EXPECT study group. Doua J, et al. Among authors: sarnecki m. Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):541-550. doi: 10.1007/s10096-023-04738-y. Epub 2024 Jan 18. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38236365 Free PMC article.
Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study.
Doua J, Rodríguez-Baño J, Froget R, Puranam P, Go O, Geurtsen J, van Rooij S, Vilken T, Minoru I, Yasumori I, Spiessens B, Tacconelli E, Biehl LM, Thaden JT, Sarnecki M, Goossens H, Poolman J, Bonten M, Ekkelenkamp M; COMBACTE-NET Consortium/EXPECT Study Group. Doua J, et al. Among authors: sarnecki m. Infection. 2024 Jun;52(3):1073-1085. doi: 10.1007/s15010-023-02163-z. Epub 2024 Jan 25. Infection. 2024. PMID: 38267801 Free PMC article.
A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.
Arconada Nuin E, Vilken T, Xavier BB, Doua J, Morrow B, Geurtsen J, Go O, Spiessens B, Sarnecki M, Poolman J, Bonten M, Ekkelenkamp M, Lammens C, Goossens H, Glupczynski Y, Van Puyvelde S; COMBACTE-NET Consortium/EXPECT Study Group. Arconada Nuin E, et al. Among authors: sarnecki m. J Antimicrob Chemother. 2024 Sep 3;79(9):2142-2151. doi: 10.1093/jac/dkae182. J Antimicrob Chemother. 2024. PMID: 39001716 Free PMC article.
Epidemiology of invasive Escherichia coli disease in adults in England, 2013-2017.
Blum M, Geurtsen J, Herweijer E, Sarnecki M, Spiessens B, Reynolds Diogo G, Hermans P, Thelwall S, Bhattacharya A, Verstraeten T, Poolman J, Hope R. Blum M, et al. Among authors: sarnecki m. Epidemiol Infect. 2025 Jan 6;153:e4. doi: 10.1017/S0950268824001584. Epidemiol Infect. 2025. PMID: 39757943 Free PMC article.
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Baden LR, Stieh DJ, Sarnecki M, Walsh SR, Tomaras GD, Kublin JG, McElrath MJ, Alter G, Ferrari G, Montefiori D, Mann P, Nijs S, Callewaert K, Goepfert P, Edupuganti S, Karita E, Langedijk JP, Wegmann F, Corey L, Pau MG, Barouch DH, Schuitemaker H, Tomaka F; Traverse/HVTN 117/HPX2004 Study Team. Baden LR, et al. Among authors: sarnecki m. Lancet HIV. 2020 Oct;7(10):e688-e698. doi: 10.1016/S2352-3018(20)30229-0. Lancet HIV. 2020. PMID: 33010242 Free PMC article. Clinical Trial.
24 results